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ABSTRACT 
leptin is a 16kDa peptide hormone that has recently been implicated in 
human reproductive processes. like other hormones, leptin exerts its 
ir.ftuence through its receptor. Of the three major isoforms of the receptor 
(OB-Ra, OB-Rb, and 08-Re), OB-Ra (the dominant short form) has been 
implicated in transport processes within rat and human placentas, suggesting 
a role for it in implantation and pregnancy maintenance. 
The peroxisome proliferator-activated receptors (PPARs) are ligand-
dependent transcription factors that are a subfamily of nuclear hormone 
receptors. PPARs form heterodimers with another nuclear hormone receptor, 
RXRa, before binding to PPAR response elements (PPREs). Recently 
PPARy/RXRa heterodimers have been implicated in trophoblast 
differentiation, thus playing a key role in human implantalion and 
placentation. 
The present study used Western Blot analysis to quantify the presence of 
Ob-R and PPARy protein in human placental tissue from first and second 
trimesters, and at term (n=9, n=10, n=12 respectively). PPARy and OB-Ra 
were found at ail stages of pregnancy. levels of 08-Ra were significantly 
lower in second trimester than ·,n first trimester or at term (p<0.01, one-way 
AN OVA). Interestingly, two different molecular weight (MW) protein bands of 
PPARy were found, one at - SSkDa and another at -BOkDa. The 80kDa 
PPARy protein decreased from first to second trimester and then increased 
to maximal levels at term (F=14.437, p<0.0001, one-way ANOVA), and the 
SSkDa PPARy protein was maximal in first trimester, fell in the second 
trimester, and remained at this level until tenm (F=3. 793394, p<O.OS, one-way 
ANOVA). Furthermore, the 80kDa protein was greater than the SSkDa at all 
stages of pregnancy (first trimester p<O.OOS, second trimester p<0.0001, 
term p<0.0001). 
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The presence of 08-Ra and PPARy over the three stages of human 
pregnancy demonstrates they are important in implantation and pregnancy 
maintenance, and this may aid in our understanding pathological conditions 
such as miscarriage and intrauterine growth retardation (IUGR). 
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CHAPTER 1: 
INTRODUCTION 
14 
1.1 BACKGROUND TO THE STUDY 
Normal implantation and placentation are critical for a successful pregnancy. 
Approximately 70% of all pregnancies fail to reach full term (Norwitz, Schust, 
& Fisher, 2001 ). Of all pregnancies that are lost, 75% are due to failure of 
implantation. Not only is implantation important but also maintenance of the 
pregnancy after implantation is essential. The incidence of miscarriage after 
implantation is estimated to be 25 to 40% (Norwitz et al., 2001). "The 
maintenance of early pregnancy is inextricably linked with placental grov.th 
and differentiation" (Norwitz et al., 2001, p.1405). 
Successful implantation is the end result of complex molecular interactions 
between the uterine endometrial epithelium and a blastocyst (Norwitz et al., 
2001). The blastocyst actively participates in a complex dialogue with the 
endometrial lining during implantation and placental growth (Hill, 2001). 
Important molecules in this communication process include cytokines, growth 
factors, aJhesion molecules, apoptotic factors and angiogenic factors (Hill, 
2001; Simon, Dominguez, Remohi, & Pellicer, 2001 ). Of these, the honmone 
leptin and the group of nuclear hormone receptors known as peroxisome 
proliferator-activated receptors (PPARs) are potentially important factors for 
both implantation and pregnancy maintenance. 
The hormone Leptin is a 16kDa peptide hormone and is a product of the 
Obese (Ob) gene. The main site of leptin production is adipose tissue and it 
was originally described as an adipocyte-derived signalling molecule, 
involved in the control of body weight and energy expenditure (Auwerx & 
Staels, 1998). Leptin exerts its effects through the leptin receptor (08-R) 
(Tartaglia et al., 1995), and the mouse, rat and human placentas have been 
shown to express leptin and leptin receptor (Masuzaki et al., 1997; Senaris et 
al., 1997; Henson, Swan, & O'Neil, 1998; Smith & Waddell, 2002). 
Recent studies have described important roles for leptin in reproduction and 
neuroendocrine signalling (Auwerx & Staels, 1998; Cunningham, Clifton, & 
Steiner, 1999; Moschos, Chan, & Mantzoros, 2002), and research has shown 
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that human placental tissue synthesizes leptin (Senaris et al., 1997), and 
leptin receptors are present in the human endometrium end decidua, 
potentially participating in the implantation process (Simonet al., 2001). 
Gonzalez et al. (2000) suggest that leptin and leptin receptors may be part of 
the embryonic-endometrial dialogue during human embryo implantation. 
Further evidence suggests that placentalleptin may be cru~,al for 
angiogenesis, placental and fetal growth, and immunomodulation (Ashworth 
etal., 2000; Hoggard, Haggarty, Thomas, & Lea, 2001). Furthermore, leptin 
secretion has been demonstrated to be regulated by steroid hormones, and 
this may link leptin with mechanisms supporting pregnancy maintenance 
(Henson & Castracane, 2000). 
PPARs comprise an important subfamily of the nuclear hormone receptor 
superfamily (Rosen & Spiegelman, 2001 ). PPAR gamma (y) is a ligand-
dependent nuclear hormone receptor that is involved in such pathways as 
adipogenesis, control of cellular differentiation and proliferation, and the 
maintenance of insulin sensitivity (Vamecq & Latruffe, 1999; Rosen & 
Spiegelman, 2001). Barak et al. (1999), found PPARy to be crucial for 
successful placentation in mice. These researchers found that PPARy 
deficiency severely compromises maternal-fetal exchange functions. 
Furthermore, PPARy null embryos showed evidence of myocardial thinning, 
and PPARy was demonstrated to be necessary for normal placental 
vascularisation (Barak et al., 1999). 
1.2 SIGNIFICANCE OF THE STUDY 
Infertility related to the process of implantation and poor placental growth is a 
major problem in obstetric medicine, and implantation failure and miscarriage 
are considered to be major biological causes of the low reproductive rate in 
humans (Bulletti, Flamigni, & Giacomucci, 1996). There are variations in both 
placental structure, and the process of embryo-maternal interactions between 
species, and animal models are therefore often unreliable, and their 
relevance to human implantation processes are unclear (Norwitz et al., 
2001). Human placental tissue will be used in this study in order to try and 
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overcome some of these limitations, and identify the stage of human 
pregnancy in which PPARy and OB-R are likely to have important roles. No 
known studies to date have compared PPARy expression in normal human 
placental tissue over the three trimesters of pregnancy, and only a few 
studies have quantified the leptin receptor protein throughout human 
pregnancy (Henson et al., 1998; Bodner et al., 1999). 
It is necessary to understand the complex molecular mechanisms behind 
normal human implantation processes so that factors which may be involved 
in pathological conditions such as implantation failure, miscarriage and 
intrauterine growth retardation (IUGR) may be identified. This may lead to 
methods of improving the likelihood of a successful birth. 
1.3 EXPERIMENTAL OBJECTIVE 
The overall objective of this thesis was to use Western Blot analysis to 
examine 08-R and PPARy protein expression over the course of human 
pregnancy, to test the hypotheses that: 
1. PPARy proteins are present in human placental tissues throughout 
pregnancy. 
2. OB-R and PPARy protein levels change throughout pregnancy. 
3. PPARy and OB-R proteins have a role during the process of 
implantation and pregnancy maintenance. 
1.4 EXPERIMENTAL DESIGN 
Human placental tissue was collected through first and second trimesters 
and at term of pregnancy. PPARy protein and OB-R protein were measured 
by Western Blot analysis at each stage. 
17 
CHAPTER2: 
LITERATURE REVIEW 
18 
2.1 IMPLANTATION 
"Implantation of the blastocyst to the uterine wall represents a highly critical 
point during early human gestation" (Sherer & Abulafia, 2001 p. 3). 
Implantation involves four basic steps. (1) Apposition, or placement of the 
blastocyst into the uterine cavity; (2) attachment of the blastocyst to the 
endometrial surface epithelium; (3) invasion of the trophoblast into 
endometrial tissues; and (4) growth of placental tissues, including 
vasculogenesis and angiogenesis (Hill, 2001). Recent research 
demonstrates that both maternal and embryonic factors have roles in the 
implantation process (Hill, 2001; Sherer & ADJiafia, 2001; Simonet al., 
2001 ). The endometrium and blastocyst secrete hormones, cytokines, and 
growth factors to prepare the uterus for implantation. Dysregulation of any 
factors in this process may be involved in either failed implantation or 
pregnancy failure (Hill, 2001; Simon et al., 2001 ). Progesterone and human 
·;horionic gonadotrophin (hCG) are secreted in large amounts by the 
syncytiotrophoblast and have a role in the trophoblast invasion (Bischof, 
Meisser, & Campana, 2000). Trophoblast invasion is due to an active 
biochemical process. According to Bischof, Meisser & Campana (2000), the 
invasive behaviour of cytotrophoblastic cells (CTBs) is due to their ability to 
secrete matrix metalloproteinases (MMPs), which are controlled by a tissue 
inhibitor of MMPs (TIMP), that inhibits their invasiveness. MMPs are a family 
of approximately seventeen human zinc-dependent endopeptidases 
collectively capable of degrading all components of the extracellular matrix 
(ECM) (Bischof et al., 2000). CTBs behave like metastatic cells except that 
they are only transiently invasive (during the first trimester). This 
invasiveness is normally limited to the endometrium and the proximal third of 
the myometrium (Bischof et al., 2000). Hence, there is both temporal and 
spatial regulation of invasion. Types of regulators involved in trophoblast· 
endometrial reactions include hormones, cytokines, growth factors, ECM 
glycoproteins, adhesion molecules, apoptotic factors, and angiogenic factors 
(Bischof et al., 2000; Hill, 2001; Simonet al., 2001). Angiogenesis is the 
development of new capillaries from existing vessels, and is essential for 
normal implantation and placentation (Sherer & Abulafia, 2001 ). Abnormal 
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angiogenesis has been implicated in disrupted implantation and placentation, 
as well as early pregnancy loss. Certain angiogenic growth factors are now 
known to be essential for angiogenesis, including vascular endothelial growth 
factor (VEGF), placental growth factor (PIGF), platelet-derived growth factor-
AA (PDGF-AA), transforming growth factor a. (TGFa.), and TGFp (for review 
see Sherer & Abulafta, 2001). Leptin, leptin receptor and PPARy have also 
been implicated in this process (Sierra-Honigmann et al., 1998; Xin, Yang, 
Kowalski, & Gerritsen, 1999) 
2-2 DECIDUA 
The decidua is the modified endometrium after implantation and is also the 
functional layer of the pregnant endometrium (Moore & Persaud, 1993). The 
decidua is formed following the endometrial reaction which occurs in 
response to blastocyst implantation and subsequently leads to 
decidualisation (Castellucci & Kaufmann, 1995). Decidualisation is 
characterised by enlargement of the endometrial stromal cells, an increase in 
the number and complexity of cytoplasmic organelles, and most importantly a 
corresponding increase in secretory and synthetic activities of the 
endometrium (Castellucci & Kaufmann, 1995). 
There are three regions of the decidua; (1) the decidua basalis, which lies 
deep to the conceptus and forms the maternal component of the placenta, (2) 
the decidua capsularis; the superficial portion overlying the conceptus, which 
degenerates and disappears by about week 22 of pregnancy, (3) the decidua 
parietalis, which lines the uterine wall (Moore & Persaud, 1993). 
The decidua is involved in the endometrial-embryonic dialogue during 
implantation processes, and it has been postulated to be involved in 
modulation of immune reactions during pregnancy. Lymphocytes make up 
about 10% of all cells found in the decidua and most of these are natural 
killer (NK) cells (Benirschke & Kaufmann, 1995). 
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2.3 PLACENTATION 
Following implantation, trophoblast cells pmliferate rapidly and invade the 
surrounding endometrium. As the endometrium is invaded, maternal blood 
vessels are trapped to form lacunae, which fill with maternal blood 
(Cunningham, MacDonald, Gant, Leveno, & Gilstrap, 1 993). As lacunae join, 
a complicated lacunar network (labyrinth) is formed, which is partitioned by 
trophoblastic columns and comprised of the intervillous space and primary 
villous stalko, respectively (Cunningham et al., 1993), and is the beginning of 
a primitive uteroplacental circulation. The lacunar network later becomes the 
intervillous space of the mature human placenta (Moore & Persaud, 1 993). 
As invasion of the endometrium proceeds, two layers of trophoblast form; the 
inner cytotrophoblast, and the outer syncytiotrophoblast (Moore & Persaud, 
1 993). PPARy is thought to be important in the process of trophoblast 
differentiation (sP.e later). The syncytiotrophoblast (syncytium) is a 
multinucleated mass without recognisable cell boundaries. It produces 
secretions which enable the blastocyst to penetrate the endometrium (Moore 
& Persaud, 1993), and lines the intervillous space, extending over surfaces of 
all chorionic villi as well as over the inner surfaces of the chorionic and basal 
plates. The syncytiotrophoblastic surface is almost entirely covered in 
microvilli, that provide a vast maternal-fetal exchange zone. There have been 
many studies of the structural and functional significance of this layer, 
including research into surface enzymes, receptors for transplacental 
hormones, growth factors, and immunological factors (for reviews see 
Bischof et al., 2000; Norwitz et al., 2001). The cytotrophoblast is mitotically 
active, and forms new cells that migrate into the syncytiotrophoblast. Here 
the cells lose their membranes and become part of the syncytium (Moore & 
Persaud, 1 993). Thus, cytotrophoblastic cells are the stem cells of the 
syncytium, supporting its growth and regeneration (Castellucci & Kaufmann, 
1995). 
Oxygenated blood and nutrients enter the lacunae from maternal spiral 
arteries, and deoxygenated blood and waste products are removed via the 
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veins of the uterus (Moore & Persaud, 1993). A fully mature maternal blood 
circulation through the placenta may not develop until the end of the first 
trimester, at about 10 to 12 weeks of the pregnancy (Johnson & Everitt, 
2000).The maternal and fetal circulations pass clos~ to each other but do not 
actually mix. In the intervillous space maternal blood flows around the fine 
terminal villi containing fetal capillaries. Placental blood constitutes about 
10% of the total maternal cardiac output by the end of the pregnancy 
(Johnson & Everitt, 2000).Siow blood velocity in the spiral endometrial 
arteries is thought to protect the early conceptus (pre-embryo) from being 
dislodged by spurts of blood, as well as giving plenty of time for the exchange 
of metabolites at the placental interface. A similar slowing of the blood occurs 
on the fetal side of the circulation, where there is a massive expansion in 
cross~sectional area of blood vasculature due to a profusion of vascular 
branching, and terminal capillary dilations (Johnson & Everitt, 2000). Nutrition 
of the conceptus is initially histiotrophic (via uterine secretions and decidua), 
and changes to haemotrophic as the placental blood supply develops 
(Johnson & Everitt, 2000). 
2.4 PLACENTAL GROWTH 
As pregnancy progresses, the placenta grows more rapidly than the uterus 
(Craven, Zhao, & Ward, 2000). The percentage of decidual surface area 
occupied by the placenta increases from 3% in the first trimester to 26% by 
the end of the pregnancy (Craven et al., 2000). The diameter of the placenta 
grows from approximately 5 em at 11 weeks, to 28 em at 38 weeks (Craven 
et al., 2000). Growth in thickness of the placenta continues until about the 
eighteenth week of pregnancy with the increase in thickness being due to 
branching of the stem villi (Moore & Persaud, 1993). Craven, Zhao, & Ward 
(2000) propose that floating villi implant in decidual veins during early 
pregnancy at sites distant from the existing placental bed, contributing to the 
process of lateral placental growth. Thus, areas of decidua marginalis 
become decidua basalis. 
22 
2.5 THE MATURE HUMAN PLACENTA 
The placenta is discoid in shape, with an average diameter of 22 centimetres. 
It is approximately 2.5 centimetres thick at the centre and weighs on average 
470 grams (Benirschke & Kaufmann, 1995).1t is 'haemomonochorial', 
meaning that the trophoblastic surface is in direct contact with maternal blood 
(Johnson & Everitt, 2000). It is also described as a 'chorio-allantoic' placenta, 
which is one that develops from the blastocyst wall and becomes fully 
vascularised from the allantois (the primitive embryonic bladder) (Johnson & 
Everitt, 2000). 
2.5.1 Placental Structure 
The placenta is both a fetal and maternal organ and is made up of the 
chorionic plate (fetal portion), and the basal plate (maternal portion), which 
together enclose the intervillous space (Benirschke & Kaufmann, 1995). The 
maternal surface has a 'cobblestone' appearance due to cotyledons (lobes) 
visible on its surface and grooves on the surface are formed by placental 
septa. The maternal surface is covered with maternal decidua basalis 
(Johnson & Everitt, 2000). 
The fetal surface is covered with amnion and attached to the chorionic plate. 
Chorionic villi, which are vascularised with fetal blood project from tile 
chorionic plate into the intervillous space. Here they are bathed in matern~l 
blood which circulates through the intervillous space (Benirschke & 
Kaufmann, 1995). Some villi extend from the chorionic plate to the decidua 
and serve as anchoring villi (Cunningham et al., 1993). Where the intervillous 
space disappears at the placental margins, the chorionic plate and the fetal 
plate fuse to form the chorion laeve (smooth chorion) (Benirschke & 
Kaufmann, 1995). 
2.6 VILLI 
Anchoring villi (stem chorionic villi) anchor the chorionic sac and the placenta 
to the decidua basalis, and the villous chorion is attached to the decidua 
basalis by the cytotrophoblastic shell (Moore & Persaud, 1993). Within villi, 
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fetal vessels are connected to the fetal circulatory system via the chorionic 
plate and the umbilical cord (Benirschke & Kaufmann, 1995). 
All villi have the same basic structure throughout the placenta, although 
individual villi have been shown to have differing functional specifications. 
Most fetal-maternal exchanges occur in placental villi, as well as the many 
metabolic and endocrine activities of the placenla (Castellucci & Kaufmann, 
1995). Within villi, fetal vessels are connected to the fetal circulatory system 
via the chorionic plate and the umbilical cord (Benirschke & Kaufmann, 
1995). 
2.6.1 Development of Villi 
Villi can be first distinguished by about the twelfth day after fertilisation 
(Cunningham et al., 1993). These primary chorionic villi are finger-like 
projections of the chorion (Moore & Persaud, 1993). Secondary chorionic villi 
are formed early in the third week, when mesenchyme grows into the primary 
chorionic villi and forms a core of loose connective tissue. Villi at this stage 
cover the entire surface of the chorion (Moore & Persaud, 1993). Tertiary villi 
(stem villi) are formed when angiogenesis occurs in the mesenchymal cells 
(Cunningham et al., 1993). The blood vessels soon become connected with 
the embryonic heart, and by the third week embryonic blood is circulating 
through the capillaries of the chorionic villi (Moore & Persaud, 1993). Both 
fetal and maternal blood vessels are now functional and placental circulation 
is established (Cunningham et al., 1993). 
Until the eighth week, chorionic villi cover the entire surface of the chorionic 
sac. As the sac grows, the blood supply is reduced to a large proportion of 
villi that eventually degenerate, producing the smooth chorion (chorion laeve) 
(Moore & Persaud, 1993). At the same time, villi associated with the decidua 
basil is (maternal component of the placenla) rapidly increase in number, 
branch profusely, and enlarge. This area becomes the villous chorion 
(chorion frondosum) and forms the fetal component of the placenta (Moore & 
Persaud, 1993). 
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2.6.2 Histological Structure of Villi 
The layers of a villus externally to the core consist of syncytiotrophoblast, 
villous cytotrophoblast (Langhan's cells), trophoblastic basement membrane, 
and finally the stromal core of the villus (Castellucci & Kaufmann, 1995). 
As described previously the syncytiotrophoblast is a continuous, 
multinucleated layer that lines the intervillous space. It does not consist of 
individual cells, and it is viewed as a single continuous structure (Moore & 
Persaud, 1993). 
Cytotrophoblastic cells (Langhan's cells) lie between the syncytiotrophoblast 
and the basement membrane. As mentioned earlier they are the stem cells of 
the syncytium, supporting its growth and regeneration. In early pregnancy, 
this layer is nearly complete but later becomes discontinuous, as survival of 
the syncytium depends on cytotrophoblastic fusion. Basement membrane 
surrounds the stromal core of the villi. Its main function is to support the 
trophoblastic epithelium. The villous stroma at the core of the villi is 
composed of various types and amounts of connective tissue fibres, ground 
substance, and fetal blood vessels (Castellucci & Kaufmann, 1995). Types of 
fixed connective tissue cells in the villous stroma include; 
mesenchymal cells, reticulum cells, fibroblasts, myofibroblasts, Hofbauer 
cells, mast cells and plasma cells (Castellucci & Kaufmann, 1995). 
2.7 PLACENTAL FUNCTION 
The placenta is an endocrine organ that perfonms many diverse functions. 
Firstly, it provides hormonal support for the developing embryo. Hormones 
synthesised by the placenta include human chorionic gonadotropin (hCG), 
human chorionic thyrotropin (hCT), human chorionic adrenocorticotropin 
(hCACTH), progesterone, estrogen, relaxin, somatomammotrophins 
including human placental lactogen (hPL), human growth hormone (hGH-V) 
and prolactin (Benirschke & Kaufmann, 1995; Martini & Welch, 1998). 
Secondly, it provides for the exchange of materials across the placental 
interface by various transport processes. These materials include gases, 
electrolytes, maternal hormones, waste products (urea, uric acid, bilirubin), 
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water, glucose, steroid hormones, as well as drugs and infectious agents. 
Thirdly, it performs many fetal metabolic functions as a substitute for the still 
immature fetal organs, including gas transfer, excretory functions, 
hematopoiesis, synthetic and secretory functions, and catabolic and 
resorptive functions (Benirschke & Kaufmann, 1995). 
2.8 INCIDENCE OF MISCARRIAGE 
The probability of conceiving a clinically recognised pregnancy within a given 
cycle has been estimated to be about 25%. However, this becomes closer to 
32% when unrecognised pregnancies are included (Wilcox et al. cited in 
Cramer & Wise, 2000, p. 333). This suggests that a number of infertile 
women may actually be experiencing recurrent unrecognised pregnancy 
losses (Cramer & Wise, 2000). The incidence of infertility is estimated to be 
10 to 15% of all couples (Reyniak cited in Bulletti et al., 1996, p.119), and 
some of this is due to implantation failure and early pregnancy loss. 
Fertilization and the earliest development of the embryo do not lead 
inevitably to a sustained pregnancy and successful birth. Loss of the human 
conceptus is common and can occur at any stage of pregnancy (Johnson & 
Everitt, 2000). Only 50 to 60% of all conceptions advance beyond 20 weeks 
of gestation (Norwitz et al., 2001). Evidence suggests that up to 50% of all 
conceptions produce zygotes that do not survive the cleavage stage (during 
the first week after fertilisation), resulting in failure of implantation. Of those 
embryos that have faulty implantation the average survival time is 8 weeks, 
with 20% failing to complete 20 weeks of development (Martini & Welch, 
1998). Failed embryo implantation is the cause of 75% of lost pregnancies, 
which as a result often remain undetected. It is also a major cause of those 
embryos lost in assisted reproduction (Norwitz et al., 2001). 
Reproductive failure can also be due to spontaneous abortion (miscarriage) 
or recurrent abortion. Recurrent abortion is usually diagnosed as at least 
three consecutive miscarriages (Bulletti et al., 1996). The incidence of 
pregnancy loss after successful implantation is estimated to be 25 to 40% 
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(Norwitz et al., 2001). The cumulative result of losses both before and after 
implantation is that only 15 to 20% of human conceptions survive to a 
successful birth (Johnson & Everitt, 2000). 
2.9 AETIOLOGY OF MISCARRIAGE 
Chromosomal anomalies are responsible for miscarriage in at least 50% of 
all clinically recognised pregnancies, (Bulletti et al., 1996; Cramer & Wise, 
2000; Johnson & Everitt, 2000). It has been suggested however, that the 
largest single cause of pregnancy loss is through failure of implantation, 
which has been estimated to be as high as 78% in humans (Webb & Glasser 
cited in Bulletti et al., 1996, p. 120). Conceptus loss before implantation has 
been attributed to a variety of reasons (for reviews see Bulletti et al., 1996; 
Cramer & Wise, 2000). 
Although a large percentage of recognised pregnancies fail due to 
chromosomal anomalies, it is not known to what extent these anomalies 
influence conceptus loss in unrecognised pregnancies. These pregnancies 
possibly represent the highest percentage of human reproductive failure 
(Bulletti et al., 1996; Norwitz et al., 2001). An overwhelming 40 to 60% of 
miscarriages are of either uncertain or unknown origin (Bulletti et al., 1996; 
Johnson & Everitt, 2000). 
2.10 LEPTIN AND LEPTIN RECEPTOR (OB-R) 
Leptin is a 16k0a hormone and is a product of the obese (Ob) gene. It was 
first described as an adipocyte-derived signalling factor involved in the 
control of body weight and energy expenditure (Auwerx & Staels, 1998; 
Hoggard, Crabtree, Allstaff, Abramovich, & Haggarty, 2001 ). The main site of 
leptin production is adipose tissue (Zhang et al., 1994), but it is also present 
in other tissues. It has been found to be present in rat brain and pituitary 
(Morash, Li, Murphy, Wilkinson, & Ur, 1999; Jin et al., 2000), the human 
pituitary gland (Jin et al., 1999), the human and rat stomach (Bado et al., 
1998; Mix et al., 2000), and human mammary epithelial cells (Smith-Kirwin et 
al., 1998). Masuzaki et al. (1997) and Senaris et al. (1997) were the first to 
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report that leptin is synthesised in and secreted from the human placenta. In 
vitro studies undertaken to measure leptin production by placental tissue 
found that it produces large amounts of this hormone (Linnemann et al., 
2000). Recent studies have examined potential roles for placental leptin, 
including fetal growth, immunomodulation, haematopoiesis and angiogenesis 
(Auwerx & Staels, 1998; Sierra-Honigmann et al., 1998; Cao, Brackenhielm, 
Wahlestedt, Thyberg, & Cao, 2001; Hoggard, Haggarty et al., 2001; Moschos 
et al., 2002), and there is a large body of GVidence indicating that leptin has 
roles in reproduction (Sabogal & Munoz, 2001; Moschos et al., 2002). 
Observational studies have demonstrated that states of leptin excess, 
deficiency, or resistance, may be associated with abnormal reproductive 
function (For review see Moschos et al., 2002). Cheung et al. (1997) 
demonstrated that in female rats leptin acted to restore the normal timing of 
puberty following modest growth retardation imposed by food restriction. 
Food restriction had already been shown to delay the onset of puberty 
(Cheung et al., 1997). Similarly, when leptin was injected into normal 
prepubertal female mice it caused an earlier onset of reproductive function 
than in controls, suggesting that leptin acts as a signal triggering puberty 
(Chebab, Mounzih, Lu, & Lim, 1997). Animal experiments and observational 
studies indicate that a rise in leptin levels may be the earliest signal of the 
onset of puberty and may contribute to the activation of the hypothalamic-
pituitary-gonadal (HPG) axis, resulting in an increase in sex steroid 
production (Moschos et al., 2002). Recent studies show that leptin influences 
the regulation of FSH, LH, ACTH, cortisol, and GH concentrations (Barash et 
al., 1996; Jin et al., 1999; Ozata, Ozdemir, & Licinio, 1999), and leptin gene 
expression itself is regulated by a variety of hormones, growth factors, and 
cytokines (for review sre Moschos et al., 2002). 
Leptin exerts its effects by interacting with its receptor (08-R) located in the 
central nervous system and in peripheral tissues (Auwerx & Staels, 1998). 
The leptin receptor belongs to the class 1 cytokine receptor family, and has 
been found at all points along the HPG axis (Moschos et al., 2002), 
suggesting that leptin plays an important role in the modulation of the 
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reproductive axis (Cunningham et al., 1999). It has at least six splice variants 
(08-Ra to 08-Rf), and the various isoforms have identical extracellular 
domains, with either long (-300 amino acids), or short (-30 amino acids) 
intracellular domains (da Silva, 8jorbaek, Uotani, & Flier, 1998; Cunningham 
et al., 1999). 08-Ra, 08-Rb and 08-Re have been identified in the rat and 
mouse placentas (Hoggard et al., 1997; Seeber, Smith, & Waddell, 2002; 
Smith & Waddell, 2002). 08-Rb is the dominant long form of the receptor 
and 08-Ra the dominant short form (Hoggard et al., 1997; Huang, Wang, & 
li, 2001). 08-Re is the soluble form of the receptor and circulates in the 
plasma (da Silva et al., 1998; Huang et al., 2001). OB-Rb is considered to be 
the signalling form of the receptor (Ashworth et al., 2000), while 08-Ra is 
thought to participate in transporting leptin across the blood-brain barrier, and 
is expressed predominantly in the choroid plexus (Tartaglia, 1997). Smith & 
Waddell (2002) suggest that placental expression of 08-Ra, 08-Rb, and 
08-Re is likely to mediate leptin transport in the fetus and placenta. They 
found that 08-Ra and 08-Re mRNA expression increased substantially in 
the period of maximal growth in the rat placenta (Day 16 to Day 22), whereas 
08-Rb remained relatively stable (Smith & Waddell, 2002). The increase in 
08-Ra was specific to the site of maternal-fetal exchange (the placental 
labyrinth zone) which they suggest is consistent with increased transport of 
maternalleptin to the fetus in late pregnancy (Seeber et al., 2002). 
Several studies have localised 08-R to the syncytiotrophoblast of the human 
placenta by in situ hybridisation and immunohistochemistry. (Henson et al., 
1998; Bodner et al., 1999; Ashworth et al., 2000; Hoggard, Haggarty et al., 
2001). Bodner et al. (1999) comment that this indicates a role for the receptor 
in the growth of the placenta and/or fetus, and Henson et al. (1998) suggest it 
is indicative of the placenta's function as an endocrine organ. They 
hypothesise that there is likely to be a regulatory association between leptin 
and the steroid hormones, that may be basic to the maintenance of 
pregnancy (Henson & Castracane, 2000). 
Expression of leptin and 08-Rs in the human ovary, oocyte, endometrium, 
embc•o, and placenta, implicate them in implantation and early embryonic 
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development (Karlsson et al., 1997; Craven et al., 2000; Gonzalez et al., 
2000; Kitawaki et al., 2000; Sabogal & Munoz, 2001; Simonet al., 2001). 
Kitawaki et al. (2000) were the first to demonstrate OB-R expression in the 
human endometrium. They found leptin receptor expressed in decidual tissue 
from early human gestation, and observed that whereas OB-R was 
expressed in the human endometrium, leptin was not. They suggest that 
leptin may play a specific role in interacting with other growth factors and 
cytokines during the implantation process (Kitawaki et al., 2000). Gonza •• ;_ et 
al. (2000), demonstrated leptin and its receptor to be expressed in secretory 
endometrium, and in cultured endometrial epithelial cells (EECs), and 
suggest that leptin is part of the embryonic-endometrial dialogue during the 
adhesion phase of human embryonic implantation. They hypothesise that the 
blastocyst and endometrium may communicate during implantation through 
leptin and its receptor. Simon &tal. (2001), reported that human blastocysts 
and EECs secrete leptin, providing evidence to show leptin's presence and 
regulation at the human embryonic and endometrial surface. 
Interestingly, in a study comparing peripheral maternalleptin levels with 
placentalleptin levels in baboon pregnancy, Henson et al. (1999) found 
maternalleptin concentrations were positively corr1lated with gestational 
age, whereas placentalleptin mRNA levels were negatively correlated with 
gestational age. These differences may imply changing roles for leptin with 
advancing pregnancy. The researchers comment that these changes are 
likely to be common to baboon and human pregnancies (Henson et at., 
1999). Moreover, significantly lower concentrations of serum leptin observed 
in women who subsequently miscarried suggest that leptin may have a role 
in preventing miscarriage (Laird, Quinton, Anstie, Li, & Blakemore, 2001). 
Malik et al. (2001) showed leptin to be a requirement for fertility, conception 
and implantation in the mouse, but observed that once pregnancy was 
established it was not required for maintenance of pregnancy. In contrast 
Mounzih, Qui, Ewart-Toland, & Chebab (1998) found that leptin was not 
essential for implantation, gestation, or fetal growth in mice, but it may be 
implicated in the regulation of maternal nutrition and metabolic adaptation 
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during pregnancy and lactation. They demonstrated a complete failure of 
lactation in leptin-deficient (ob/ob) female mice. 
Many studies to date have used mouse and rat models to investigate the 
roles of leptin and its receptors in pregnancy. Due to the complexity of 
interactions between leptin, OB-R, and other molecules, the utilisation of 
animal models for the investigation of leptin action in human pregnancy has 
produced conflicting results. As leptin action may differ significantly between 
species, more human studies are warranted (Henson et al., 1998). 
2.11 PEROXISOME PROLIFERATOR-ACTIVATED 
RECEPTOR GAMMA (y) 
Peroxisome proliferator-activated receptors (PPARs) were first discovered in 
1990 (Vamecq & Latruffe, 1999). They are ligand-dependent transcription 
factors belonging to the family of nuclear hormone receptors (Vamecq & 
Latruffe, 1999; Rosen & Spiegelman, 2001). There are thre~ major isoforms 
of PPARs; PPARa., PPARP, and PPARy (Vamecq & Latruffe, 1999), that 
together control many cellular and metabolic processes (Wahli, 2002). 
PPARs have become an attractive target for pharmaceutical intervention in 
such metabolic diseases as obesity, diabetes, and hyperlipidaemia, and 
recently, they have been shown to have a role in epidermal differentiation 
and repair (Wahli, 2002). 
PPARy expression is dominant in white adipose tissue, and in immune cells 
in rodents and humans (Fajas et al., 1997; Vamecq & Latruffe, 1999; Clark et 
al., 2000; Padilla, Leung, & Phipps, 2002). PPARy forms heterodimers with 
retinoid X receptors (RXRs) which then bind to PPAR-responsive elements 
(PPRE) within the promoters of PPARy genes (Tarrade, Schoonjans, 
Guibourdenche et al., 2001). Moreover, PPARy is involved in further complex 
interactions with various ligands, coactivators, and corepressors (Vamecq & 
Latruffe, 1999; Qi, Zhu, & Reddy, 2000; Rosen & Spiegelman, 2001 ), that 
have yet to be fully understood. Interestingly, Western Blot studies of PPARy 
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protein to date have reported finding PPARy protein at varying molecular 
weights (see Table 1). 
Table 1: Suggested PPARy Molecular Weights 
Tissue PPARy Authors Year examined Molecular Weight(MW) 
Capparuccia et al. 2002 human placenta 60kDa 
Fajas et al. 1997 human adipose 60kDa 
Padilla, Leung, & 2002 human B cells 80kDa Phipps 
Tarrade, 
Schoonjans, 2001 human placenta 57kDa Guibourdenche et 
al. 
Tarrade, 
Schoonjans, Pavan 2001 human placenta 50kDa 
et al. 
Waite et al. 2000 human placenta 55kDa 
Two isoforms of PPARy are found in mice and humans, PPARy 1 and 
PPARy 2. Fajas et al. (1997) showed that the isoform PPARy1 is the 
predominant form in humans. PPARy has been described as the 'master 
regulator' of adipocyte differentiation (Vamecq & Lfltruffe, 1999, p.145), and it 
promotes cell differentiation in many cell types incluaing hepatocytes, 
fibroblasts, myocytes, keratinocytes, monocytes, and macrophages. PPARy 
has been implicated in cancer, atherosclerosis, type 2 diabetes, the 
regulation of insulin sensitivity and inflammatory responses (Vamecq & 
Latruffe, 1999; Rosen & Spiegelman, 2001; Wahli, 2002). 
Barak et al. (1999) showed PPARy to be necessary for normal placental 
development in the mouse, and found PPARy deficiency caused an inability 
of fetal blood vessels to form a vascular network. These authors 
demonstrated that PPARy deficiency interferes with both trophoblast 
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differentiation and placental vascularisation, leading to severe myocardial 
thinning and death of the embryo (Barak et al., 1999). Fetal-maternal 
exchange functions were severely compromised due to impaired 
vascularisation. This study revealed a novel developmental dependence of 
the heart on a functional placenta. Similar placental defects to those 
mentioned occurring in PPARy null mice were observed in RXRa-deficient 
mice (Wendling, Chambon, & Mark, 1999). Recent studies have implicated 
PPARy in trophoblast differentiation in humans (Schaiff et al., 2000; Tarrade, 
Schoonjans, Pavan et al., 2001). Furthermore, several studies have 
investigated the role of PPARy in inhibiting angiogenesis. It has been found 
to be expressed at high levels in tumour endothelium, and researchers have 
demonstrated that PPARy ligands can inhibit primary tumour growth through 
antiangiogenic effects (Xin et al., 1999; Panigrahy et al., 2002) 
Recently, Cui et al. (2002), reported that the loss of the PPARy gene in 
oocytes and granulosa cells led to impaired fertility. These researchers 
commented that although progesterone levels were decreased, and 
implantation rates reduced, they were not able to identify the exact 
mechanisms involved. 
PPARy has been localised by immunohistochemistry to human 
syncytiotrophoblasts and cytotrophoblasts (Schaiff et al., 2000; Waite et al., 
2000; Tarrade, Schoonjans, Pavan et al., 2001; Capparuccia et al., 2002; 
Wang, Fujii, & Knipp, 2002). Only a few studies have quantified PPARy 
protein in placental tissue in human pregnancy. Wang et al. (2002) observed 
PPARy in rat and human placentas. Tarrade, Schoonjans, Pavan et al. 
(2001) measured PPARy in first trimester placentas only, and Schaiff et al. 
(2000) in term placentas only. Recently, Capparuccia et at. (2002) observed 
PPARy protein expression in early pregnancy and at term. These 
researchers found no significant quantitative difference in PPARy expression 
between first and third trimester placentas. Their results demonstcated that 
PPARy expression was downregulated in gestational trophoblastic diseases 
such as choriocarcinoma and hydatidiform moles, reinforcing earlier findings 
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that PPARy is involved in the differentiation and invasiveness of placental 
trophoblast cells (Barak et al., 1999; Schaiff et al., 2000; Tarrade, 
Schoonjans, Pavan et al., 2001). Further studies are needed to elucidate the 
role of PPARy over the course of human pregnancy. 
2.12 PPARy- OB·R INTERACTION 
Yamauchi et al. (2001) observed a potential interaction between leptin and 
PPARy/RXRa heterodimers. The authors were examining the roles of these 
receptors in insulin sensitivity, and reported that increases in PPARy/RXRa 
activity were associated with decreased serum leptin levels (Yamauchi et al., 
2001). Indeed this may imply a similar pattern of expression in placental 
function, and could be linked to recent evidence that PPARy/RXRa 
heterodimers and OB·Ra are both involved in transport processes within the 
placenta (Seeber et al., 2002; Smith & Waddell, 2002; Wang et al., 2002). 
2.13 SUMMARY 
Human embryo implantation and placental growth are vital to achieving a 
successful birth. A deeper understanding is needed of the complex 
interactions between molecules at the fetal-maternal interface. Recent 
research indicates that leptin receptors and PPARy appear to hnve essential 
roles in these communications. Deciphering these may contribute to reducing 
the high incidence of unexplained infertility and miscarriage, by providing 
possibilities for early clinical interventions in either pre-pregnancy or 
pregnancy itself. 
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CHAPTER3: 
MATERIALS AND METHODS 
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3.1 ETHICAL CONSIDERATIONS 
Ethics approval was obtained for this study from Edith Cowan University 
Faculty of Communications, Health and Science Ethics Sub-Committee for 
the conduct of Human Research, and the King Edward Memorial and 
Princess Margaret Hospitals Institutional Ethics Committees (EC 02·229). 
3.2 TISSUE COLLECTION 
Thirty-one samples of placental tissue were collected in total. Placental tissue 
was obtained following caesarean deliveries, at term (n=12), from King 
Edward Memorial Hospital, Subiaco, Western Australia. First trimester 
placental tissue (n=9), was collected following elective terminations at 
Nanyara, Rivervale, Western Australia, and second trimester placental tissue 
(n=1 0), was collected following elective terminations from Marie Stapes 
International, Midland, Western Australia. Term placentas were examined 
and weighed prior to cutting several small samples (NO.Scm3) from the 
maternal surface which were then put into 1.5mL Eppendorf tubes, snap 
frozen on liquid nitrogen, and stored at ·SO'C for later Western Blot analysis. 
Due to the sensitive nature of, and the small amounts involved, first and 
second trimester placental tissues were not examined or weighed. However, 
as with term placentas, tissue was collected in 1.5mL Eppendorfs, snap 
frozen on liquid nitrogen, and stored at ·SO'C for subsequent Western Blot 
analysis. A patient information sheet was given to all patients and signed 
consent was obtained prior to collection (see Appendices 1 and 2 for the 
Form of Consent and Patient Information Sheet). First trimester placentas 
were from gestational weeks 6, 7 (x4), 8 (x2), 9, and 11. Second trimester 
placentas were from gestational weeks 13 (x2), 14, 15 (x3), 16, 17, 19 and 
20. 
3.3 PROTEIN EXTRACTION FOR WESTERN BLOT 
ANALYSIS 
Protein was extracted from placental tissues following a standard laboratory 
protocol. Placental tissues were homogenised in RIP A Lysis Buffer (See 
Solutions and Buffers for Western Blot in Appendix 4) using a Polytron PT 
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1200 homogeniser ((Kinematica, Switzerland). One tablet of Complete, 
EDT A-Free Protease Inhibitor Cocktail Tablets (Roche Diagnostics GmbH, 
Mannheim, Germany), and 50)!1 of 0.1 M sodium orthovanodate were added 
to 50)!1 of RIPA Lysis buffer immediately prior to homogenisation. The cell 
lysate was then transferred to 1.5mL Eppendorf tubes and centrifuged at 
11 000 x g at 4'C for 25 minutes. Following centrifugation the supernatant 
was collected, aliquoted into 1.5mL Eppendorf tubes, and stored at -20'C. A 
preliminary study found this protein fraction to be suitable for both leptin 
receptor and PPARy detection. 
3.3.1 Bradford Protein Assay 
The Bradford protein assay was used to determine the total protein content of 
the placental tissue protein extracts. This assay is a dye-binding assay in 
which a colour change of dye occurs in response to various concentrations of 
protein. It works by the action of Coomassie Brilliant blue G-250 dye (CBBG). 
The absorbance maximum for a solution of CBBG shifts from 465nm to 
595nm when binding to protein occurs. 
3.3.1.1 Reagents 
Bio-Rad Protein Assay Dye Reagent Concentrate and Bio-Rad Protein Assay 
Standard II Lypophilised bovine serum albumin (BSA) were purchased from 
Bio-Rad Laboratories, Hercules, USA. 
3.3.1.2 Preparation of Standard Curve 
The dye reagent was prepared by diluting 1 part Dye Reagent Concentrate 
with 4 parts ddHzO and then filtered. Reconstituted BSA was mixed with 
ddH20 to a concentration of 1 mg/mL. Cuvettes were set up in duplicate, and 
a blank containing ddH20 was prepared (see Table 3 in Appendix 3). 
3.3. 1,3 Preparation of Protein Samples 
Protein samples were taken out of -20'C storage, thawed on ice, diluted in 
ddH20, and prepared in duplicate. Preliminary studies were performed to 
determine the correct dilution factor. Dilutions of 40x, 100x, and 250x were 
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tested and a dilution factor of 1 OOx was found to be suitable. However, 
readings from eight samples did not fall within the standard curve and were 
then diluted 200x which gave an acceptable concentration. 
The 100x dilution was prepared by diluting 5~1 of protein sample in 495~1 
ddH20 and the 200x solution was prepared by adding 5~1 of protein sample 
to 995~1 ddH20. 
3.3.1.4 Spectrophotometry 
Semi-micro cuvettes, polystyrene, 1 em path, 1.5mL, and a SmartSpec 3000 
spectrophotometer were purchased from Bio-Rad Laboratcries, Hercules, 
USA. Cuvettes for standard curve and cuvettes conteining diluted protein 
samples were vortexed and incubated at room temperature for at least five 
minutes before reading ir. the spectrophotometer. The spectrophotometer 
was set to 595nm. The assay is monitored at 595nm and thus measures the 
CBBG complex with the protein. 
3.4 WESTERN BLOT ANALYSIS 
3.4.1 Reagents 
The Kaleidescope Prestained Standard (broad range, #161-0324), and 
Prestained SDS-PAGE Standard (high range, #161-0309);Criterion Precast 
gels 7.5% and 10% (forOB-R and PPARy respectively); running buffer, and 
Laemmli sample buffer, were all purchased from Bio-Rad Laboratories, 
Hercules, CA, USA. The premixed transfer buffer and p-mercaptoethanol 
were from ICN Biornedicals, Aurora, Ohio, USA. Ponceau S solution was 
from Sigma Chemical Co, StLouis, MO, USA; and Tween 20 from Asia 
Pacific Specialty Ghemicals Ltd, Seven Hills, NSW. 
3.4.2 Equipment 
The Criterion Electrophoresis Cell Tank, Criterion Blotter Tank, PowerPac 
200 power supply, Criterion Gel Holder Cassettes, Criterion Gel/Blot 
Assembly Tray, lmmunu-Biot polyvinylidene diflouride (PVDF) membrane, 
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filter paper and fibre pads (9.5x15.2cm), were all purchased from Bio-Rad 
Laboratories, Hercules, CA, USA. 
3.4.3 Buffers and Solutions 
Buffers and solutions for Western Blot analysis were made up following 
standard protocols, and are shown in Appendix 4. 
3.4.4 Preparation of Samples for Gel Loading 
Extracted protein samples were prepared for loading onto gels immediately 
prior to loading. A total volume of 20fll was loaded into each well. 
3.4.4.1 Reagents and Solutions 
~-mercaptoethanol was purchased from ICN Biomedicals Inc. Aurora, Ohio, 
U.S.A. RIP A Lysis Buffer and Laemmli sample buffer were made to standard 
protocols (See Appendix 4) 
3.4.4.2 Calculation of Protein Extract to Load 100flg of Protein 
For each orotein sample, the protein concentration for that sample 
(spectrophotometer reading) was used to calculate the amount of protein (in 
fll) to load for 1 OOJ.lg. SJ.ll Laemmli sample buffer, containing 5% ~­
mercaptoethanol was then added to that volume of protein, to which was 
then added RIP A lysis buffer to a final volume of 20~tl. ~-mercaptoethanol is 
used to reduce disulphide linkages in solubilising proteins for gel 
electrophoresis (see Table 2). 
Table 2: Preparation of protein sample for loading 
Protein Laemmli Final Protein volume to RIPALysis co71cent~~on Sample Buffer Volume load for 1 OOJJ.Q ().11) Buffer ("I) ma/mL . f"ll f"ll 
e.a.40 2.5 5 12.5 20 
Samples "ore then given a short vortex mix (-4 seconds) followed by a 6 
second mini-spin. The protein samples, together with the appropriate 
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molecular weight marker (MW) were incubated at 55'C for 10 minutes prior 
to loading onto gels. 
3.4.5 Loading the Gels and Electrophoresis 
Protein (100~g) was loaded into each lane, and the first lane in oach gel 
contained 12 ~I of MW standard (broad range for PPARy and high range for 
OB-R). The precast gels (10% for PPARy and 7.5% for OB-R) were set up in 
the Criterion tank according to the manufacturer's instructions (Bio-Rad 
Laboratories, Hercules, CA, USA.), and each gel was run at 80V for 20 
minutes, and then at 150V for -80 minutes, until the dye front reached the 
bottom of the gel. 
3.4.6 Protein Transfer 
Following electrophoresis, the gel was placed in transfer buffer for 15 
minutes to equilibrate. The lmmuno-Biot PDVF membrane was placed in 
100% methanol for a few seconds, until translucent, prior to transferring it to 
transfer buffer to equilibrate. The Criterion Blotter transfer apparatus and 
gel/membrane sandwich were prepared according to the manufacturers 
instructions (Bio-Rad Laboratories, Hercules, CA, USA.), and the transfer 
was run for 60 minutes at 1 OOV on ice. 
3.4.7 Ponceau S Staining 
Membranes were removed from the transfer tank and placed in a shallow 
dish filled with PBS and Tween. Ponceau S stain (4-SmL) was poured onto 
the membranes to visualise and check for the even loading and transfer of 
proteins. All dye was then removed from the membranes with multiple 
washes in PBS and Tween. 
3.4.8 PPARy and OB-R lmmunoblotting 
Membranes were blcoked at room temperature in 0.01M PBS and Tween 
containing 5% non-fat milk powder for one hour, and incubated overnight at 
4'C with primary antibody (rabbit polyclonal antibody PPARy (H-100) SC-
7196, Santa Cruz Biotechnology, Santa Cruz, CA, USA), diluted 1:200 in 
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blocking solution; or rabbit (OB-R PA 1-053, Affinity Bioreagents, Inc, Golden, 
CO, USA), diluted 1:2000 in blocking solution. Membranes were then washed 
5 times in 0.01 M PBS and Tween, and incubated at room temperature for 1 
hour in secondary antibody (goat anti-rabbit lgG conjugated, SC-2030, 
Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted 1:20 000 in 
blocking solution. Membranes were then washed for 6 "5 minutes in 0.01M 
PBS and Tween, followed by one rinse of- 20 seconds in 0.01M PBS 
(without Tween). 
3.4.9 Visualisation of Bands 
Detection of bound antibody was performed with the enhanced 
chemiluminescence Western Blotting detection kit (Amersham Pharmacia 
Biotech UK ltd). The SuperSignal West Pico Substrate solution (Pierce 
Chemical, Rockford IL, USA) was prepared by combining an equal volume of 
l Luminal/Enhancer solution and stable peroxide solution (to 10mL total). 
Membranes were placed in the solution for 5 minutes with gentle shaking. 
Membranes were then exposed to Hyperfilm ECL (Amersham Pharmacia 
Biotech UK ltd) and Hypercassette 8" x 1 0" (Amersham Pharmacia Biotech 
UK Ltd) for 1-10 minutes and developed on an Agfa Scopix LR 5200 
developer. Membranes were stored at 4'C on 0.01M PBS prior to stripping 
and reprobing. 
3.4.10 Stripping and Reprobing the Membranes 
Membranes were stripped by incubating in stripping solution (See Appendix 
4) for 30 minutes at 70'C. They were then washed for 2 x 10 minutes in 
0.01M PBS and Tween. The stripped membrane was then incubated (as 
before) in SuperSignal West Pico Substrate working solution and exposed to 
film. The membrane was considered stripped when no bands were visible 
after 10 minutes exposure. 
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3.4.10.1 Non-Specific Antibody Binding 
To check for non-specific antibody binding, membranes were incubated 
overnight at 4'C in blocking solution without the primary antibody, and then 
proceeding as previously described (See section 3.4.8). 
3.4.11 Quantification and Statistical Analysis 
Bands on the immunoblot images were quantified using Scion Image 
analysis (Scion Corporation, USA). All data are expressed as mean ±SEM. 
Changes in quantities of PPARy and OB-R over the three stages of 
pregnancy were determined by one-way AN OVA and Least Significant 
Difference (LSD) tests. Differences in quantities of the different molecular 
weights of PPARy protein (80kDa and 55kDa) in each trimester were 
assessed by unpaired two tailed t-tests. A correlation analysis was performed 
to assess possible relationships between (1) weeks of gestation and 80kDa 
PPARy, (2) weeks of gestation and 55kDa PPARy, (3) weeks of gestation 
and OB-Ra, (4) 80kDa PPARy and OB-Ra, and (5) 55kDa PPARy and 
OB-Ra. 
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4.1 WESTERN BLOT ANALYSIS OF PPARy PROTEIN 
Western blot analysis showed the presence of both a high molecular weight 
(MW) protein band of approximately 80kDa, and a less intense lower MW 
protein band of approximately 55kDa over the three stages of pregnancy 
(see Figure 1 ). No signals were detected in membranes that were not 
exposed to primary antibody. The 80kDa band was more intense than the 
55kDa band over all stages of pregnancy (first trimester 1=3.66, p<0.005; 
second trimester 1=7.80, p<0.0001; term 1=21.74, p<0.0001, unpaired two 
tailed t-test: see Figure 2). Quantification of the 80kDa PPARy protein signal 
showed that it decreased from first to second trimester and then increased to 
maximal levels at term (F=14.437, p<0.0001, one-way ANOVA; p<0.05, 
p<0.001, p=0.0799, LSD test). The 55kDa PPARy protein signal was 
maximal in first trimester, fell in second trimester and remained at this level at 
term (F=3.793394, p<0.05, one-way ANOVA; p<0.05, p<0.05, p=0.733, LSD 
tost). 
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Figure 1. Western Blot of PPARy protein in human placental tissue over the 
course of human pregnancy. Arrows on the left indicate the MW marker. 
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Figure 2. Quantification of Placental PPARy protein (BOkDa band and 55kDa 
band) over the three stages of human pregnancy. First trimester n;9, second 
trimester n;1Q, term n;12. Bars indicate mean± SEM. At each stage of 
pregnancy those values without common notations differ significantly. 
4.2 CORRELATION BETWEEN GESTATIONAL AGE AND 
PPARy 
Because of the wide range of gestational ages examined, a correlation 
analysis was performed to assess a possible association between the week 
of gestation and level of PPARy. There was a significant positive correlation 
between the 80kDa MW bands and weeks of gestation (r-0.5894, r';0,3474, 
p;O.OOOS), and a significant negative correlation (r= -0.379, r';0.1436, 
p<O.OS) between the amount of SSkDa protein and advancing gestation. 
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4.3 WESTERN BLOT ANALYSIS FOR OB·Ra 
Western blot analysis showed the presence of a 1 OOkDa band corresponding 
to the short form (08-Ra) of the leptin receptor, at all stages of pregnancy 
(see Figure 3). 
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Figure 3. Western Blot analysis of 08-Ra protein in human placental tissues 
throughout human pregnancy. Arrows on the left represent the MW marker. 
1 OOkDa band is the 08-Ra protein. 
Quantification of OB-Ra protein levels showed a significant decrease from 
first trimester to second trimester, and then a significant increase back to 
first trimester levels at term (F=5.73684, p<0.01, one-way AN OVA: see 
Figure 4). 
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Figure 4. Quantification of Placental OB-R protein over the three stages of 
human pregnancy. First trimester n=9, second trimester n=10, term n=12. 
Data expressed as mean ± SEM. Bars without common notations differ 
significantly. OB-Ra protein levels changed significantly over the course of 
pregnancy (F=5.73684, p<0.01, one-way ANOVA). Levels were lower in 
second trimester compared to first trimester and term (p<0.05, p<0.05, 
p=0.4070, LSD test). 
4.4 CORRELATION BETWEEN GESTATIONAL AGE AND 
OB-Ra 
As with PPARy, a correlation analysis was performed to assess for a possible 
relationship between gestational age and OB-Ra. There was no significant 
correlation between OB-Ra and gestational age (r-0.2914, r'=0.0849, 
p=0.1182, two tailed t-test). 
4.5 COMPARISON OF BOkDa PPARy AND 08-Ra 
Observations showed a similarity in the quantities of and pattern of the 
PPARy BOkDa protein and OB-Ra over the three trimesters. To test if there 
was an association between the two proteins, a correlation analysis was 
performed showing a significant association (r-0.6937, r'=0.4812, p<0.0001, 
two tailed 1-test). The same test performed on the 55kDa PPARy and OB-Ra 
did not show a significant correlation (r-0.232, r'=0.0540, p=0.2168, two 
tailed t-test). 
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,. 1 
••• DISCUSSION 
The experimental objective of this study was to examine OB-R and PPARy 
protein expression throughout the course of human pregnancy. The present 
study has shown the presence of two different molecular weights of PPARy 
protein, at 55kDa and 80kDa respectively, over the three trimesters of 
pregnancy, and OB-R protein at 1 OOkDa representing the predominant short 
form of leptin receptor, OB-Ra. 
There was a significantly different pattern of 80kDa and 55kDa MW proteins 
over the course of pregnancy, with the 80kDa protein increasing and the 
55kDa protein decreasing as pregnancy advanced. The 80kDa PPARy 
protein signal decreased from first to second trimester, then increased to 
maximal levels at term. The 55kDa PPARy protein signal was maximal in first 
trimester, fell in second trimester, and remained at this level until term. 
Furthermore, there was a strong positive correlation between the 80kDa 
protein and weeks of gestation, and a strong negative correlation between 
the 55kDa protein and weeks of gestation. 
Unlike previous studies (Fajas et al., 1997; Waite et al., 2000; Tarrade, 
Schoonjans, Guibourdenche et al., 2001; Tarrade, Schoonjans, Pavan et al., 
2001; Capparuccia et al., 2002; Padilla et al., 2002), that have reported one 
band at varying molecular weights in human placental tissue, the present 
study showed evidence of two PPARy protein bands, at 55kDa and 80kDa. 
These could possibly represent two PPARy isoforms. Further studies are 
needed to fully characterise the two PPARy proteins identified in this study. 
Molecular mechanisms involving PPARy/RXRa heterodimers, and their 
interactions with ligands, coactivators, and corepressors are extremely 
complex (Vamecc & Latruffe, 1999; Qi et al., 2000; Rosen & Spiegelman, 
2001 ), and are beyond the scope of this thesis. 
The presence of PPARy at all stages of pregnancy shown in this study 
suggests a functional role for PPARy in implantation, and continuing 
throughout pregnancy. Recent studies on human placental tissue have 
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suggested a role for PPARy in trophoblast differentiation and invasion 
(Schaiff et al., 2000; Tarrade, Schoonjans, Pavan et al., 2001; Capparuccia 
et al., 2002). A significantly higher level of 55kDa PPARy protein was 
observed in the first trimester compared to second and at term, as well as a 
significantly higher level of BOkDa PPARy protein in the first trimester 
compared to second. Early pregnancy is a crucial time for trophoblast 
differentiation and invasion. Furthermore, these processes are essential for 
successful implantation to occur. 
OB-Ra protein was observed at all stages of pregnancy in the present study. 
The results show no significant differences between levels of OB-Ra in the 
first trimester and at term, similar to the observations of Henson et al. (1998) 
who also examined first trimester and term human placental tissue and found 
no difference. These authors however did not examine second trimester 
placentas, unlike the present study showed that OB-Ra levels decrease 
significantly in second trimester. 
In the rat placenta, Smith & Waddell, (2002) found that OB-Ra protein 
expression increased significantly from Day 16 to Day 22 (the period of 
maximal growth; term ; Day 23). However, it is difficult to ascertain whether 
Day 16 of rat pregnancy is equivalent to the first trimester or second trimester 
in human pregnancy. If Day16 of rat pregnancy is the equivalent to second 
trimester in human pregnancy then their findings support the findings of the 
present study. 
The functional importance of leptin and its receptors in human implantation 
and pregnancy have been discussed recently in several studies, Ashworth et 
al. (2000), and Hoggard, Haggarty et al. (2001 ), both describe roles for leptin 
and its receptors in processes such as fetal growth, angiogenesis, 
haematopoiesis, immunomodulation, and in numerous complex molecular 
interactions at the fetal-maternal interface. The results of the present study 
suggest an important functional role for the short form of the leptin receptor 
in implantation and pregnancy. Higher levels of OB-Ra in first trimester and 
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at term than in second trimester, suggest a functional role for the receptor at 
these times. These roles are likely to be in angiogenesis in the first trimester, 
and in transport functions between the placenta and mother and/or fetus at 
term. 
The present findings show a strong correlation between OB-Ra and PPARy 
over all stages of pregnancy. Both PPARy and OB-Ra have been implicated 
in angiogenesis (Sierra-Honigmann et al., 1998; Barak et al., 1999; Xin et al., 
1999; Ashworth et al., 2000; Hoggard, Haggarty et al., 2001; Panigrahy et al., 
2002) and placental transport functions (Vamecq & Latruffe, 1999; Seeber et 
al., 2002; Smith & Waddell, 2002; Wang et al., 2002). The present study 
raises the possibility of an interaction between OB-Ra and PPARy during 
human embryo implantation and throughout pregnancy, in processes that are 
essential to implantation and placentation. 
5.2 LIMITATIONS OF THE STUDY 
The present study could have been enhanced by examining placental OB-R 
and PPARy mRNA expression by RT-PCR analysis. This however was not 
feasible at this time due to difficulties encountered in obtaining placental 
tissues, and delays in laboratory equipment set up. 
5.3 FUTURE DIRECTIONS 
Future directions for this study are firstly to investigate the regulation of 
PPARy and OB-R in human pregnancy, and secondly to examine possible 
interactions between them. The present study has contributed to our 
understanding of normal placental ex. ·ession of OB-R and PPARy, which 
may facilitate further studies of pathological conditions such as miscarriage 
and IUGR. An unexpected result in this study was the presence of two 
different molecular weight PPARy protein bands throughout pregnancy 
(55kDa and 80kDa). Further characterisation of these bands is warranted. 
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5.4 CONCLUSION 
In conclusion, the present study has demonstrated the presence of both OB-
Ra and PPARy protein over the three stages of human pregnancy. High 
levels of each protein, in early human pregnancy and at term, suggest they 
are important in human implantation and placentation as has been shown in 
animal models. Functional roles for them are likely to be in angiogenesis, 
placental transport processes and trophoblast differentiation. Furthermore, 
this study has highlighted a possible interaction between PPI'.Ry and OB-Ra 
in pregnancy. Further studies will focus on elucidating their regulation, and 
investigating whether their downregulation is involved in pathological 
conditions such as miscarriage and IUGR. 
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7,1 APPENDIX 1 
FORM OF CONSENT 
I, 
Given names Surname 
• have read the information explaining the study entitles "Novel actions 
of leptin in implantation and placental function". 
• have read and understood the information given to me. Any questions 
I have asked have been answered to my satisfaction. 
• understand I may withdraw from the study at any stage and withdrawal 
will not interfere with routine care. 
• agree that research data gathered from the results of this study may 
be published, provided that names are not used. 
Dated ........................ day of .......................................... 20 .............. . 
Signature ...................................................... . 
I, ..................................................... have explained the above to the 
(Investigator's full name) 
signatory who stated that he/she understood the same. 
Signature ..................................................... . 
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7.2 APPENDIX 2 
PATIENT INFORMATION SHEET 
Novel actions of leptin in implantation and placental function 
Poor fetal growth and implantation failure remain major problems in obstetric 
care. Successful implantation is where the embryo embeds itself in the lining 
of the uterus and establishes a placenta. It is estimated that among human 
conceptions that do not advance beyond midgestation, 75% are due to 
implantation failure, and low birth weight accounts for 10% of annual child 
health costs. 
The establishment, growth and function of the placenta is of critical 
importance to the successful maintenance and completion of pregnancy. The 
placenta is effectively the lifeline of the growing fetus through its supply of 
nutrients, removal of wastes and coordination of hormone signals that help 
the fetus grow. 
Among these signals a hormone called !eptin, which is better known for its 
role in regulation of body weight has been identified as a crucial player in the 
control of fetal growth. Another molecule known as PPAR has recently been 
shown to be essential for implantation of the embryo into the uterus and the 
establishment of a normal healthy placenta. In this study we will examine 
leptin and PPAR in placental tissues from various stages of pregnancy and 
in cases of poor fetal growth and miscarriage. We will use standard 
laboratory procedures to measure the amount of these hormones in the 
placenta. 
The tests will then be done using small samples (3-4) about the size of a 
thumbnail taken from the placenta after delivery. No information that can 
identify you will be kept for these samples. No genetic information is being 
studied. It is likely that the results will be published, but no way of identifying 
you will be possible. Placentas will be disposed of following standard KEMH 
procedures once the samples have been taken. 
If you have any questions regarding this research project please contact 
Dr Peter Burton 
Scientific Director 
Concept Fertility Centre 
Telephone: 93822388 
If you have any complaints regarding the conduct of the study please contact the 
Executive Director of Medical Services at KEMH on 9340 2222 
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7.3 APPENDIX 3 
Table 3: Standard curve for the Bradford Protein Assay 
STANDARD PROTEIN PROTEIN DILUTED CONCENTRATION STANDARD ddH20 PROTEIN DYE No Jmg/ml) {ull I" I I 
1 0.00 0 25 975 
2 0.10 2.5 22.5 975 
3 0.20 5 20 975 
4 0.40 10 15 975 
5 0.60 15 10 975 
6 0.80 20 5 975 
7 1.00 25 0 975 
(The linear range of the Bio-Rad Bradford Protein Assay for BSA is 
0.2-0.9 mg/ml.) 
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7.4 APPENDIX 4 
BUFFERS AND SOLUTIONS FOR PROTEIN EXTRACTION AND 
WESTERN BLOT ANALYSIS 
RIPA Lysis buffer 
1.5M NaCI 
1M Tris-HCI pH7.5 
Triton-x-100 
Deoxycholic Acid 
10% SDS 
100mL 
50mL 
10mL 
5g 
10mL 
The volume was adjusted to 800ml with ddHzO, the pH was brought to 8.0 
with 4M NaOH, and then the volume further adjusted to 1 L with ddH20. 
Laemmli Sample Buffer 
20% SDS 6.25ml 
OTT 0.77g 
2.5M Tris pH 6.8 1.2mL 
0.5M EDTA 0.8ml 
glycerol 1.75ml 
1% Bromophenol blue 0.35ml 
The volume was adjusted to 1 Oml and the pH was brought to 6.8. 5!11 of P-
mercaptoethanol was added to 95~1 of sample buffer prior to loading the 
samples. 
Running Buffer (1x Tris/Giycine/SDS) 
0.025M Tris 
0.192M Glycine 
0.1% (w/v) SDS 
100ml of 1 Ox premixed buffer was added to 900ml of ddH20. The pH was 
brought to 8.3. 
Transfer Buffer (Tris/Giycine) 
0.025M Tris 
0.0192M Glycine 
1 packet of premixed buffer was added to 800ml methanol. The volume was 
adjusted to 4L with ddH20. The pH was brought to 8.3. 
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0.01M PBS 
NaH2PO,H20 
Na2HPO, 
NaCI 
0.8g 
S.Sg 
35.7g 
The volume was adjusted to 4L with ddH20. The pH was brought to 7.5. 
4 mL of Tween was added to 4L of 01 M PBS. 
5% (w/v) Blocking Solution 
Skim milk powder (Sg) was added to 100mL 0.01M PBS and Tween. 
Stripping Buffer 
2.5M Tris-HCI pH 6.8 
p-mercaptoethanol 
SDS 
25~1 
9.98mL 
20g 
The volume was adjusted to 1000mL with ddH20. 
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